Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading 1.9% Higher – Still a Buy?

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX)’s share price shot up 1.9% during mid-day trading on Thursday . The stock traded as high as $6.08 and last traded at $6.03. 213,587 shares were traded during trading, a decline of 27% from the average session volume of 294,099 shares. The stock had previously closed at $5.92.

Analyst Ratings Changes

Several brokerages recently issued reports on EPRX. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Eupraxia Pharmaceuticals in a research report on Monday, May 4th. Zacks Research upgraded Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 7th. Wall Street Zen downgraded Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Stifel Nicolaus began coverage on Eupraxia Pharmaceuticals in a research report on Thursday, May 21st. They set a “buy” rating and a $25.00 price objective for the company. Finally, William Blair began coverage on Eupraxia Pharmaceuticals in a research report on Monday, March 23rd. They set an “outperform” rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $18.33.

Eupraxia Pharmaceuticals Price Performance

The company has a fifty day simple moving average of $7.00 and a two-hundred day simple moving average of $7.38. The company has a debt-to-equity ratio of 0.02, a quick ratio of 19.31 and a current ratio of 19.31. The company has a market capitalization of $392.07 million, a price-to-earnings ratio of -5.74 and a beta of 0.97.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). As a group, research analysts anticipate that Eupraxia Pharmaceuticals Inc. will post -0.86 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of EPRX. Integrated Wealth Concepts LLC acquired a new position in Eupraxia Pharmaceuticals in the 3rd quarter valued at $71,000. Bank of America Corp DE raised its holdings in Eupraxia Pharmaceuticals by 402.4% in the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after acquiring an additional 10,059 shares during the last quarter. Aptus Capital Advisors LLC acquired a new position in Eupraxia Pharmaceuticals in the 4th quarter valued at $76,000. Guardian Wealth Advisors LLC NC acquired a new position in Eupraxia Pharmaceuticals in the 4th quarter valued at $76,000. Finally, Geode Capital Management LLC acquired a new position in Eupraxia Pharmaceuticals in the 4th quarter valued at $105,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.